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Summary.-The relationship between carcinoembryonic antigen (CEA) and A
antigenic determinants on the cell surface of colon-tumour cells was studied by the
ADCC assay. Antiserum prepared in 2 rabbits to an undecapeptide analogous to the
amino terminal of CEA(l -11) was found by us either to participate in (Rabbit 2) or
specifically inhibit (Rabbit 1) ADCC. The binding spectra of these two antisera and of
antiserum to the whole CEA molecule were similar. All of them react with A and
non-A colon-tumour cells as well as red blood cells of Type A (RBC-A) and their
activity was completely absorbed on RBC-A but not on B or 0. 0-type, ADCC-
reactive human sera always react with A-type colon-tumour cells and RBC-A, and
some of them with non-A colon-tumour cells also. The degree of inhibition of their
reactivity by anti-CEA(l -11) RI varied between sera, from none to almost a complete
inhibition, and is not related to whether the serum is of cancer or non-cancer origin.
Non-reactive 0-type sera contain anti-A activity demonstrable by haemagglutina-
tion and immunofluorescence. However, they cannot participate in ADCC reaction
nor inhibit it. The sera, which contain lymphocyte-dependent antibody to A-type
colon-tumour cells, lysed RBC-A, without the addition of lymphocytes or comple-
ment, in an immunologically specific way. It is concluded that the reactivity seen in
our ADCC system is related to a determinant common to A and CEA (and maybe to
other normal cross-reacting antigens) which most probably resides in the amino
terminal part of these molecules. This determinant elicits the production of lympho-
cyte-dependent antibodies in about 50o/ of people with blood group 0. Thus, the
amino terminal part of CEA is not a tumour-specific part of the CEA molecule. No
specific anti-tumour activity was found in patients' serum by this method, and claims
for its demonstration by other methods may well be related to the non-specific
activity observed here.
IN the preceding article (Shoham
& Cohen, 1979), the antibody-dependent
cellular cytotoxicity (ADCC) reaction
against human colon-tumour cells was
used to test cellular and humoral activity
in cancer patients and healthy controls.
Definite humoral activity was found in
21%0 of the sera tested. However, this
reactivity was not related to disease state
but to blood-group 0, and was apparently
anti-A activity per se. On the other hand,
"A-like activity" was demonstrated in
purified preparations of CEA (Gold &
Gold, 1973) and there is still controversy
regarding its significance. Some people
regard it as impurity due to separable A
molecules (Lo Gerfo et al., 1972), some
relate it to the blood group of the patient
and found respectively A, B or Le-
specific determinants attached to the
CEA molecule (Holburn et al., 1974) and
some claim that it is an innate characteris-
tic of the CEA molecule, unrelated to the
blood group of the patient (Gold & Gold,
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1973). The expressioni of this and other
determinants when the CEA molecule is
part of the cell surface is even less under-
stood.
The present experiments were under-
taken in order to study the relationship
between A and CEA on the cell surface,
and their relative contribution to the
ADCC reaction. In addition, the possi-
bility of demonistrating a moire specific
tumour-directed activity by using in-
hibitory antisera was also evaluated.
MATERIALS AND METHODS
Cell lines wAere the same as in the previous
study (Shoham & Cohen, 1979) but in addi-
tion, 2 other colon-tumour cell lines were
used: HCT-8 and 4788, kindly given to us by
Dr M Goldrosen from Roswell Park Memorial
Inistitute. Buffalo, N.Y., U.S. Cell cultures
Aere done as in the previous study.
Serla. Goat anti-CEA serum wA-as produced
as in Shoham & Cohen (1979). Rabbit anti-
CEA(1-11) was antiserum prepared by Dr
Arnon and her group (Arnon et al., 1976)
against a synthetic peptide corresponding to
the I-amino-acid residues of the amino
terminal portion in the sequence of CEA con-
jugated to BSA, and *was kindly given to us
bv them. Anti-A and anti-B blood grouping
serum, prepared from the blood of donors
hyperimmunized wA-ith blood-group-specific
substances, Mwas purchased from Hyland
(Div. Travenol Labs, CA). ADCC reactive and
non-reactive human sera wAere selected from
our previous study.
Lymiphocyte preparation and assay condition
for ADCC wtere as in the previous study.
Serum? absorption on RBC.-Two volumes of
serum Nith 1 volume of washed packed RBC
were mixed and incubated at 37°C for 60 min.
The procedure was repeated twice.
Mixed haemadsorption wtas used to deter-
mine the blood group of the cell lines. The
tested cells, were seeded in 24 cluster plates
(Costar, Mass.) to get confluent monolayer
cultures after overnight incubation. Then the
cultures were washed and incubated with
anti-A or anti-B serum for 30 min, washed
again, and a I% suspension of A or B RBC
in PBS was added to the treated monolayers.
Surface immnunofuorescence.-Cells were
harvested and incubated with the tested
serum for 30 min at room temperature then
washed and incubated with fluorescein-con-
jugated antiserum to the tested serum.
RESULTS
Determination of blood group of the colon-
tumour cell lines
This was done by 2 methods: mixed
haemadsorption and imnmunofluorescence
using commercial typing serum. It was
found that ACC-20 and HT-29 had blood-
group A antigen, and this was confirmed
from the known blood group of the
patients. Lines HCT-8 and 4788 were
found to be non-A (0).
Absorption of anti-CEA on RBC
Anti-CEA absorbed on RBC 0 or B
retained about the same activity as non-
absorbed serum. However, absorption on
RBC-A eliminated ADCC activity almost
completely. Similar results were obtained
with ADCC-reactive 0-type human serum
(Table I). Thus, anti-CEA prepared against
the whole CEA molecule is strongly cross-
reacting with antigen A on RB(1. There-
TABLE I.-Specific absorption of AJDCC activity of sera to A-type colon-tumour cell line
by erythrocytes
0° Specific lysis (mean +s.d.)
RBC absorption of sertum
Seriutmn tested(*
Anti-CEA
S-so
0 B
504+12 47-3: 1-8 45(0+ 0-9
46-1 +0-7 405+ -:3 :372+-2-I
A
4-1 +0-3
7-4+0-8
* Teste(I seruiim wvas use(d unItreated oIr absorbe(d orn 0, B or A RBC,
then tested for ADC( activity on HT-29 cells as (lescribedt in Materials
andl Methods. S-80 is from a patient with adenocarcinomaofthepancireas.
bloodi groulp )0.
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TABLE II.-Sensitization for and inhibition of ADCC to A-type colon-tumour cell line
by anti-CEA(1-11) sera
% Specific lysis (mean +s.d.)
Serum tested
Anti-A
Anti-CEA
Anti-CEA(1-11) R2*
S-141
S-194
Anti-CEA(1-11) RI
S-113
Targets pretreated by
Anti-CEA
(1-11) RI
Anti-CEA (Absorbed
(1-11) RI* on A)
30-3+1-8 14-2+1-0 29-0 + 2-7
28-0+ 2-1 4-1+ 0-8 26-7 + 1-2
41-8+0-7 5-3+ 1-4 45-1+0 4
26-5+ 3-2 12-8+ 2-1 24-2 + 1-5
37-1+0-3 11-7+1-2 ND
0
0
* Anti-CEA(l-l1) was prepared in 2 rabbits (RI and R2). RI antiserum
exhibited inhibitory and R2 sensitization capability for ADCC. Target cells
were incubated directly with tested serum or after incubation with R1
antiserum or S-113 (O type non-reactive human serum).
fore, for further experiments we intro-
duced antisera prepared against a syn-
thetic peptide corresponding to the 11
amino-acid residues of the amino terminal
portion of the sequence of CEA:anti-CEA
(1-11). This is obviously a different
determinant from the known A deter-
minant.
ADCC with A-type colon-tumour cells
Antisera prepared in 2 rabbits (RI and
R2) against CEA(-1l1) conjugated to
BSA, both found to be active in the
bacteriophage-inactivation assay for CEA
(Arnon et al., 1976), were compared for the
ADCC activity on A-type colon-tumour
cells. Surprisingly, these 2 antisera differed
completely in their ADCC activity. RI
antiserum was completely devoid of
activity, whereas R2 antiserum was more
potent than anti-CEA (Table II). How-
ever, when cells were incubated first with
anti-CEA(1-11) RI and then with anti-
CEA(I-11) R2, the ADCC activity of the
R2 antiserum was almost completely in-
hibited. Thus, Rabbit 1 produced anti-
bodies that cannot participate in the
ADCC reaction, but were avidly bound to
CEA either in the phage assay or on the
cell surface. Similar inhibitory activity of
anti-CEA(1-11) RI was also exerted on
anti-CEA activity. On the other hand, the
activity of anti-A, as well as that of
reactive 0-type human serum, was only
partially inhibited. Moreover, if RI anti-
serum was absorbed on RBC-A it com-
pletely lost its inhibitory activity to all
the sera tested. A non-reactive 0-type
human serum (S-113) was completely
without inhibitory activity, although it
contains strongly agglutinating anti-A
and anti-B (Table II).
We tested the possibility of using the
inhibitory activity of anti-CEA(I-11) RI
for differentiating between cancer and
non-cancer sera. The results (Table III)
indicate that the degree of inhibition
varies considerably from 0 to 90%. How-
ever, the degree of inhibition does not
correlate with the disease state of the
patient.
ADCC with non-A colon-tumour cells
Table IV compares the ADCC activity
of several sera on A (ACC-20 and HT-29)
and non-A (HCT-8 and 4788) colon-
tumour cell lines. As expected, anti-A
reacted only with the two A lines. Anti-
CEA and anti-CEA(1-1I) R2 reacted with
all 4 lines, although the results with non-A
cell lines are lower than those with A cells.
It has to be emphasized, however, that
non-immunological factors can contribute
to such differences. The reactive 0-type
human sera differed in their ability to
react with non-A cell lines; some react
S-113
32-5 + 0-5
30-8 + 1-8
42-2 + 2-3
28-7+0-7
33-8 + 1-5
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TABLE III.--Inhibition of ADCC activity of human sera by anti-CEA(l-l 1) R1
O0 Specific lysis
Targets pretreate(l by
Seru( n Anti-CEA InihibitionI
tested1* Source (1-11) RI of lysis
S-167 Non-cancer 16-4 + 1-0 17-1 + 0-6
S-114 Breast ca. 317+ 2-8 27-0+ 1-8 1'3
S-135 Alelanoma 20.5 5+0 9 14-2+ 1-1 30
S- 187 Non-cancer 26:3+ 1-5 18-6+ 05 :32
S-162 Non-cancer 21 0 + 1-2 14 8 + 0-8 :3:3
S-141 Breast ca. -26-6+0-7 12-2+ 1*0 5:3
S,8-74 Colon cancerei 46-5 + 1-9 12-4 +0-6 73
8-8:3 Bladder ca. 40-8 + 1-1 5-3 + 0-2 87
5-184 Nonl-caIncer 20-2+ 1-2 2-0+0-3 90
* ADI)(C-reactive blood-group 0 sera were teste(1 foi their
activity on H1T-29 cells. Results arranged accor(ling to the dlegree
of inhibition exertedI)b the pretreatment.
TABLE IV. AD1CC activity of different sera on A and non-A colon-tumour cells
00f Speific lysis
Cell line testd(l
Seirumn testedl A(-20() HT-29 HCT-8 4788
Aniti-A 11-3 + 0-4 15-5 + 0-6 1-5 + 0-8 0-7 + 0-2
Anti-CEA :33-4+0-7 24-0+ 1-: 17-8+ 1-I 14-6+05
Antti-(EA(1-I1)1{2 42-1 + 1-8 21-1 + 1-5 10-8+0-6 8-5+0-8
8-52 18-7+ 1-1 21-3+0(9 16-3+07 4-1+0-4
8-61 2-1 +0-5 4-3+(-8 1-5+ 1-0 1-8+0-7
S-74 :7-2 + 1-5 26-7 + 2-:3 3-3 + 0-4 ND)
8-187 18-+2-1 2) 2-0-8 15-4+2-1 21-8+1-:3
8-176 35-9+ 1-0 16-2+ 1-2 4-5+0-7 2-8+ 1-0
With only one of these lines (i.e. 8-352),
some Avith the 2 linles (S-197) an(d some (1o
not react at all (S-74, S-176).
ADCC with RBC
In the first experiments we compare(l
the ADC'C activity of the (lifferent seia on
LT-29 anid RBC-A (Table V). The spon-
taneouis release (with oi- without pre-
incuibation in niormal goat serum, NGS)
wras muich lower with RBC than with
HT-29. The presence of lymphocytes di(d
not clhange the (legree of 541r release.
However, in the presence of reactive sera,
a remarkable (lifference wvas noticed be-
tween the HT-29 cells andl RBC. The
presence of the heat-inactivated serum
alone was enoulgh to cauise 51Cr release
from RBC to aldegree equtal or slightly
lower than wvith lymphocytes, wrhereas
wN-ith HT-29 the activitv of the serum was
expressed only in the presence of lympho-
cvtes. Both anti-(EA anid anti-CEA(1 -I 1)
17
R2 were reactive with RBC-A to about the
same degree. Only human sera which
reacted in ADCC against tumour cells
xs-ere reactive against RBC-A without
need for lymphocyte assistance, or partici-
pation of complement (inactivated serum;
some of the experiments in the presence of
carrageenan).
In the following tables the results will
be expressed as 00 51Cr release rather than
00 specific lysis, in order to account for the
antibody effect per se.
The immutnological specificity of the
reactions was tested by using 0, A and
B-type RBC (Table VI). As expected,
commercial anti-A and anti-B prepara-
tions reacted only wAith A or B cells,
respectively, with essentially the same
iresuilts with or without adding lympho-
cytes. Anti-CEA(1-I1) R2 and anti-CEA
reacted with RBC-A only. The most
interesting results were with 0-type
human sera. Sera which do not react withJ. SHOHAM AND M. COHEN
TABLE V.-Serum activity with or without the addition of lymphocytes on
and RBC-A
0 5lCr releaset
Serum test,ed*
NGS
Anti-A
Anti-B
Anti-CEA
Anti-CEA(l - 11) R2
S-56 (-)+
S-77 (+)
S-84 (-)
S-114 (+)
Target cell HT-29
Lymphocytes added:
+_
27-4+0-7
26-1+0-2
49-8 + 1-4
29-5 + 1-1
55-2+2-4
66-4 + 1-9
36-0 + 0-8
61-0 + 2-2
32-7 + 1-3
65-2 + 1-6
26-8 + 1-3
28-7 + 1-0
27-2+0-7
27-5 + 1-2
25-1 + 1-5
26-3+0-9
27-9 + 2-1
25-8 + 0-5
29-2 + 1-7
23-6+0-8
Target cell RBC-A
+_
7-7 + 1-0
6-0 + 0-8
74-5 + 2-3
8-3 + 1-1
45-4 + 1-7
49-2+0-9
10-7+0-5
79-3 + 1-8
7-8 + 1-2
48-1 + 2-6
8-9+0-4
8-2 + 0-5
52-4 + 1-6
5-8+0-9
40-5+0-8
34-7 + 2-1
11-6+ 1-2
84-1 + 2-9
6-9+ 1-0
32-5+0-7
* Target cells were treated with one of the tested sera and then incubated
for 18 h with or without lymphocytes, as described in Materials andl
Methods.
t The results expressed as Cr release rather than % specific lysis in
order to demonstrate the peculiar behaviour of the RBC.
t The 4 last sera are 0-type human sera. The sign in brackets refers to
their reactivity in the ADCC assay on HT-29 cells.
TABLE VI. Serum activity with or without lymphocytes on RBC of blood groups
O, A and B
° 51Cr release*
NG
Ant
Ant
Ant
8-2
8-2
S-8
S-8
Target cell
RBC-O
Lymphocytes ad(ied
Serum tested +
7-6 8-3
rS 7-2 7-8
ti-A 8-0 7-5
ti-B 6-4 5-9
ti-CEA(1-11) R2 8-5 10-2 z
04(-)t 7-1 6-3
59 (+) 6-8 7-7 4
3(+) 6-1 5-5 3
4 (-) 6-5 6-1
Target cell Target cell
RBC-A RBC-B
_ ,
+ -
6-9
6-5
58-3
8-8
52-6
5-1
45-7
39-4
7-6
7-8
6-0
49-7
8-1
35-3
6-4
43-2
25-5
6-9
8-1
9-2
6-1
82-7
10-5
7-1
36-2
6-0
51-4
6-2
7-0
5-5
80-4
12-2
8-5
34-9
7-2
47-2
* The smallest significant difference (P = 0-05) between two experimental
values was 5-7.
t Signs in brackets for the 4 last sera refer to activity in ADCC on HT-29
colon-tumour cells.
HT-29 cells may be either wholly non-
reactive (S-204) or reactive to RBC-B only
(S-84). On the other hand HT-29-reactive
sera may be reactive either with RBC-A
and B (S-259) or RBC-A only (S-83).
Anti-CEA(1-11) RI was used for in-
hibition experiments on RBC-A, similar to
that done on HT-29 (Table VII). R2 anti-
serum was strongly inhibited whereas
anti-CEA and S-141 were only partially
and anti-A activity was quite unaffected.
Thus, the inhibition of serum activity was
much less effective on RBC-A than on
HT-29 cells (compare Tables VII and II).
Once more, anti-CEA(I-11) RI absorbed
on RBC-A was completely devoid of
inhibitory activity.
Binding to cell-surface immunoftuorescence
study
The antisera used in this study were
tested for their ability to bind to the cell
surface. Table VIII summarizes the re-
sults with anti-CEA and anti-blood-group
HT-29 cells
248ADCC TO HUMAN COLON-TUMOUR CELLS. II
TABLE VII.-Inhibition of serum activity on RBC-A by anti-CEA(1-1l) RJ*
Anti
(1-1]
Lymphocytes addled:
Sertum testedi + -
Aniti-A
Aniti-CEA
Anti-CEA(l - 1) R2
X-141
Anti-CEA(I-l11) R I
S-i13
4-3
56-7
57-2
16-5
33-4
4-5
4-0
5
9
3
% 5ICri release
RBC pretreatedl by:
Anti-CEA
-CEA (1-11) RI
l) RI (Absorbed on A) 8
t A , r <---
+ -+ _
4-6 6-1 5-8 4-1
i2-3 35-6 48-9 42-5
!9-8 25-2 67-3 65-1
9-2 80 31-2 18-3
,1-2 27-8 60-5 41-2
S-113
4-7
57-5
58-8
17-8
ND
4-2
60-2
53-4
14-3
* Similar experimental (lesign to Table II, see footnote there.
TABLE VIII. The binding of antisera to CEA and blood-group antigens to the
su*rface of colon-tumour cells and RBC, studied by indirect immunofuorescence
Antisertum
tested*
Aniti-CEA
Anti-CEA(1-11) R I
Anti-CEA(l - 1l) R2
Aniti-A
Aniti-B
Cell type:
HT-29 ACC-20 HCT-8 4788 RBC-0 RBC-A RBC-B
+++ +++ ++ + ++
++ ++ ++ + - + _
+ + + + _
++ + + - - - + +
- ~ - '? _-
*Cells weie inicubatedl with one of the teste(d aintisera (30 miil RT) and theni with
the appropiriate fluorescent anti-immunoglobulin serum (anti-goat, for anti-CEA,
anti-rabbit for anti-CEA(1-11) andl anti-human for anti-A and B). The table
(desci-ibes the intensity of the surface fluorescence; its morphology (liffers also among
the (lifferent sera (Fig.). The results with anti-B on HCT-8 an(d 4788 cell lines
wvere (liffictilt to initeipi-et for technical reasons.
antisera. It can be seen that anti-CEA, as
well as anti-CEA(1-11) RI or R2, react
with A and non-A colon-tumour cells and
RBC-A. However, there are differences in
the intensity and morphology of the
reaction. Anti-CEA gives the most intense
fluorescence with a more complete rim
which, in some cells, tended to patchy
distribution and even cap formation.
Anti-CEA(1-] 1) RI gave weaker and more
patchy distribution and anti-CEA(1-1 1)
R2 was the weakest, with only spots of
fluorescence (Fig. A-D). It has to be
remembered that R1 is the inhibitory and
R2 is the reactive serum in ADCC. Anti-A
was reactive with HT-29 and ACC-20 and,
of course, RBC-A, but not with HCT-8
and 4788.
O-type human sera were also tested in
this way. Most of the sera gave positive
surface fluorescence whether or not they
contained lymphocyte dependent activity
(LDA). However, with some of the sera
no fluorescence appeared, and this hap-
pened with either LDA positive ornegative
sera. The fluorescent pattern was that of a
continuous rim or patches but occasionally
more regional distribution was noticed
(Fig. E-F).
DISCUSSION
In order to evaluate the relationship
between the antigens CEA and A on the
cell surface, we introduced antisera with
apparent selectivity to one of them, anti-
CEA(1-I 1) and anti-A respectively, and
cell types which bear only one of the
antigens (non-A colon-tumour cells vs
RBC-A). Anti-CEA(1-11) from Rabbit 1
and Rabbit 2 (RI and R2) have similar
binding capacity. However, R I inhibits
and R2 participates in the ADCC reaction.
5-2
52-5
59-2
24-3
47-7
4-1
4-7
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FIGURE.-Surface fluorescence of HT-29 cells by indirect immunofluorescence stain. A-D: anti-CEA
sera. Cells incubated with goat anti-CEA, then with rabbit anti-goat IgG (A); with rabbit anti-
CEA(I-11) R1 (B) or R2 (C and D) then with goat anti-rabbit IgG. E-F: cells incubatedwithhuman
0-type ADCC reactive sera (from two cancer patients) then with anti-human IgG.
Inhibition of ADCC was demonstrated in
other systems, but it is by a mechanism
which seems to be different from the one
described here. Soluble immune complexes
(MacLennan, 1972), IgG aggregates
(Greenberg et at., 1973) or antibodies
attached to cell-surface antigens of the
effector or "third party" cells (Halloran
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et al., 1974) or even target cells (Schir-
macher et al., 1974) inhibit ADCC by
modifying the Fe portion of the involved
antibody molectule. The inhibition in our
svstem seems to be unrelated to this
mechanism. The assay procedure used by
us (preinctibation of target cells with the
test serum, which is washed out before
adding the effector cells) does not favour
the participation of either soluble immune
complexes, or aggregates of antibodies
bound to effector- cells in the reaction. The
possibility of non-specific inhibition by
coated target cells is not eliminated tech-
nically by the assay protocol, buit does not
seem to play any significant role in these
experiments. Our recent studies (data not
shown) indicate that HT-29 or RBC-A
cells coated by anti-CEA(1-Il) RI are not
inhibitory to the ADCC reaction with
HT-29 cells coated by anti-CEA( 1-11) R2.
Moreover, the similar binding capacity of
the R2 antisera and the results of absorp-
tion on RBC-A indicate that we are deal-
ing with specific antigenic blockade. The
following dliscussion is based upon this
assumption.
Anti-CEA anld anti-CEA( 1 -11) react
with A and non-A colon-tumour cells as
well as RBC-A, but not B or 0. Their
activity can be eompletely absorbed on
RBC-A but not on 0 or B. Hence, both
reagents react powerfully with A antigen.
However, it is inconceivable that this
reaction is taking place against the known
N-acetyl-D-galactosamine determinants of
the A antigen, because CEA(l-11) cer-
tainly does not contain it (Arnon et al.,
1 976) and CEA does not contain it in
many cases (Fuks et al., 1975). XVe must
asstume a common antigenic determinant
to CEA and A which resides in another
part of the molecule, and as CEA(I-1l)
corresponds to the N-terminal part of the
CEA molecule, we tentatively ascribe the
common activity to this part of the mole-
cule. However, as the carrier molecule of
the ABO antigens is most probably com-
mon to all ofthem, we further assume that
although the N terminal may be common
to other antigens (including B and 0 (H))
it is exposed conformationally only in A
and CEA. Alternatively, certain small
differences in the primary sequence of a
peptide determinant may change anti-
genicity in similar molecules like those of
the ABO system. The heterogeneity found
in the N-terminal of CEA (Wang et al.,
1976) may be cited in support of such
possibility. This molecular segment may
also participate in the cross-reactivity of
CEA with normal glycoprotein antigens
(Von Kliest, 1973) on the cell surface and
it. will be worth while to look for its
presence in them. In any case, the CEA(I-
l l) determinant is not tumour-specific at
all. However, the antiserum prepared
against it did help to solve the controversy
over the source of the "A-like site",
indicating it to be an innate and common
characteristic of both the CEA and A
molecules. This may also explain the con-
fusing observation of "CEA-like activity"
on erythrocyte membranes (Nery et al.,
1973; Taylor & Freed, 1976).
The activity of the 0-type ADCC-
reactive human sera is less clearly de-
lineated. They always react with A-type
colon-tumour cells and RBC-A, and some
of them with non-A colon-tumour cells
also. The degree of inhibition of their
reactivity by anti-CEA(1-11) RI varies
from one serum to the other, from none to
almost complete inhibition, and is not
related to the serum being of cancer or
non-cancer origin. Sometimes they also
contain anti-B activity. Hence, the reac-
tive sera contain LDA which are directed,
at least partially, to the common deter-
minant of CEA and A, as judged from the
experiments on the non-A tumour cells
and the inhibition by anti-CEA(1-II) RI.
We have no explanation of the fact that
only 50%0 of 0-type people produce LDA
active in this system, and it will be of
interest to determine whether this activity
is genetically controlled. This may be
related either to different genetic control
of immune responsiveness or to individual
differences in the antigenic determinant
involved. In this connection, the difference
between the antisera produced in the 2
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rabbits to CEA(1-11) (Ri =inhibitory,
R2 =reactive in ADCC) is also of some
interest, and seems to be related rather to
difference in immune responsiveness.
Non-reactive 0-type sera do contain
anti-A activity, which is demonstrated by
haemagglutination and immunofluores-
cence. However, they cannot participate
in ADCC reaction nor inhibit it. The
absence of inhibitory activity may be
related either to the fact that they bind
only to the N-acetylgalactosamine deter-
minant and do not block the other site, or
because they bind to the same site as the
LDA, but less avidly and are easily
replaced.
In conclusion, the reactivity demon-
strated in our system was shown to be
related to a determinant common to A and
CEA which is not N-acetyl-D-galactos-
amine. No specific anti-CEA activity was
found, and we wonder whether such
activity exists at all. The only evidence
that is cited for anti-CEA activity in
human sera is the work of Gold & Gold
(1973) and Gold et al. (1972) and the
demonstration ofCEA in immune complex
nephropathy in a patient with colon
tumour (Costanza et al., 1973). However,
both may be related to the phenomenon
described here.
One unexpected observation deserves
comment. The serum which contains
LDA active to A-type colon-tumour cells
exhibited a peculiar lytic effect on RBC-A;
the lysis took place without the addition
of lymphocytes or complement, whereas
the lysis of the antibody-coated tumour
cells was absolutely dependent on the
addition of lymphocytes. This reaction is
immunologically specific and the possi-
bilities of non-specific toxic effect of the
serum or residues of either complement or
mononuclear cells in the serum or RBC
preparations, respectively, were reason-
ably excluded. This reaction is now being
further explored by purified immuno-
globulin fractions of these sera, before
any further conclusions from this observa-
tion are drawn.
This work was supporte(1 in part, by reseach grants
6/74 ancl 3/75 from the Israel Cancer Association.
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